Validation of Saliva in the Esoterix Genetic Laboratories Fragile X Assay

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-07-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to determine if saliva samples can be used as an alternate sample type to test for fragile X. By using saliva instead of blood, it would be easier for patients to have fragile X testing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia

NCT04255680

Friedreich Ataxia

COMPLETED

Protein Synthesis in the Brain of Patients With Fragile X Syndrome

NCT00362843

Fragile X Syndrome Healthy Volunteers

COMPLETED

Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

NCT00823368

Fragile X Syndrome

COMPLETED

Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID

NCT00006335

Severe Combined Immunodeficiency

COMPLETED

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

NCT03802799

Fragile X Syndrome

ENROLLING_BY_INVITATION PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Saliva samples will be prospectively collected from subjects who have previously been tested by Esoterix Genetic Laboratories, LLC using blood specimens and diagnosed as fragile X intermediates, premutations (carriers) or full mutations (affected). Results from fragile X testing with saliva will be compared to results from the blood sample that was previously submitted to Esoterix Genetic Laboratories for testing.

Data from this study will be used for regulatory submissions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fragile X Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fragile X full mutation (affected)

Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed \>200 CGG repeats with abnormal methylation pattern; interpretation is full mutation for fragile X syndrome

No interventions assigned to this group

Fragile X premutation (carriers)

Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed 55-200 CGG repeats with normal methylation pattern; interpretation is premutation carrier of fragile X syndrome

No interventions assigned to this group

Fragile X intermediate

Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and fragile X molecular analysis revealed 45-54 CGG repeats; interpretation is intermediate, not a carrier of a fragile X expansion mutation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has previously been identified through molecular testing at Esoterix Genetic Laboratories as a Fragile X intermediate, premutation (carrier) or full mutation (affected).
* In the opinion of the subject's physician, the subject is medically stable and able to provide the required quantity of saliva.
* If Subject is at least 18 years of age:
* Subject must be willing to give written informed consent
* Subject must be willing to comply with the collection procedure
* If Subject is under 18 years of age, the legally authorized representative must give written informed consent and agree to comply with study procedures.

Exclusion Criteria

* Subject has been determined to be an individual with a normal FMR1 gene.
* Subject has a known medical condition that would cause risk to the donor or, if relevant, the fetus as a result of saliva collection.

Eligible Sex

ALL

Accepts Healthy Volunteers

No